博晖创新(300318.SZ)子公司人凝血因子Ⅷ获得药品注册证书

Core Viewpoint - The company announced that its subsidiary, Hebei Bohui Biopharmaceutical Co., Ltd., has received the Drug Registration Certificate from the National Medical Products Administration for its product, Human Coagulation Factor VIII, which is used to treat bleeding symptoms in patients with Hemophilia A and acquired Factor VIII deficiency [1] Group 1 - The approval of the Drug Registration Certificate for Human Coagulation Factor VIII enhances the company's product line [1] - The product is significant for improving plasma utilization efficiency for Hebei Bohui [1] - The drug is primarily used for the prevention and treatment of bleeding symptoms in patients with specific coagulation disorders [1]